APO Research
Talk to an analyst

APO RESEARCH · REPORT

Autologous Stem Cell & Non-stem Cell Therapies

Compare research editions
View pricing & licenses

Selected research

Industry Research

Autologous Stem Cell & Non-stem Cell Therapies Industry Research Report 2026

3 May 2026133 pages

Choose your research edition.

Industry ResearchAutologous Stem Cell & Non-stem Cell Therapies Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Autologous Stem Cell & Non-stem Cell Therapies Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Autologous Stem Cell & Non-stem Cell Therapies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Autologous Stem Cell & Non-stem Cell Therapies Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Autologous Stem Cell & Non-stem Cell Therapies Market Analysis and Forecast 2026-2032183 pages · $4,950 USD

Market perspective

The global Autologous Stem Cell & Non-stem Cell Therapies market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Autologous Stem Cell & Non-stem Cell Therapies market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Autologous Stem Cell & Non-stem Cell Therapies market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Autologous Stem Cell & Non-stem Cell Therapies market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Autologous Stem Cell & Non-stem Cell Therapies include Anterogen Co., Ltd., APAC Biotech, Bristol-Myers Squibb Company, CARsgen Therapeutics Holdings Limited, Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.), Gilead Sciences, Inc., Green Cross Holdings Co., Ltd. (GC Cell), Healiva SA and ImmunoACT, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

Read the full market overview

This report quantifies the global Autologous Stem Cell & Non-stem Cell Therapies market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Autologous Stem Cell & Non-stem Cell Therapies.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Autologous Stem Cell & Non-stem Cell Therapies Market by Company

Anterogen Co., Ltd.

APAC Biotech

Bristol-Myers Squibb Company

CARsgen Therapeutics Holdings Limited

Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)

Gilead Sciences, Inc.

Green Cross Holdings Co., Ltd. (GC Cell)

Healiva SA

ImmunoACT

Iaso Biotherapeutics

Johnson & Johnson

Lovance Biotherapeutics, Inc.

Novartis AG

Pharmicell Co., Ltd.

Regrow Biosciences Pvt Ltd.

Tegoscience

Vericel Corporation

W (Cayman) Therapeutics Co. Ltd.

Autologous Stem Cell & Non-stem Cell Therapies Segment by Type

CAR-T

Tumor Infiltrating Lymphocyte

Autologous Stem Cell & Non-stem Cell Therapies Segment by Application

Hospital

Surgery Center

Other

Autologous Stem Cell & Non-stem Cell Therapies Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Autologous Stem Cell & Non-stem Cell Therapies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Autologous Stem Cell & Non-stem Cell Therapies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Autologous Stem Cell & Non-stem Cell Therapies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Autologous Stem Cell & Non-stem Cell Therapies companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Autologous Stem Cell & Non-stem Cell Therapies Market Size by Type (2021-2026) & (US$ Million) Table 6. Global Autologous Stem Cell & Non-stem Cell Therapies Revenue Market Share by Type (2021-2026) Table 7. Global Autologous Stem Cell & Non-stem Cell Therapies Forecasted Market Size by Type (2027-2032) & (US$ Million) Table 8. Global Autologous Stem Cell & Non-stem Cell Therapies Revenue Market Share by Type (2027-2032) Table 9. Global Autologous Stem Cell & Non-stem Cell Therapies Market Size by Application (2021-2026) & (US$ Million) Table 10. Global Autologous Stem Cell & Non-stem Cell Therapies Revenue Market Share by Application (2021-2026) Table 11. Global Autologous Stem Cell & Non-stem Cell Therapies Forecasted Market Size by Application (2027-2032) & (US$ Million) Table 12. Global Autologous Stem Cell & Non-stem Cell Therapies Revenue Market Share by Application (2027-2032) Table 13. Global Autologous Stem Cell & Non-stem Cell Therapies Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Autologous Stem Cell & Non-stem Cell Therapies Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Autologous Stem Cell & Non-stem Cell Therapies Market Share by Region (2021-2026) Table 16. Global Autologous Stem Cell & Non-stem Cell Therapies Forecasted Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Autologous Stem Cell & Non-stem Cell Therapies Market Share by Region (2027-2032) Table 18. Autologous Stem Cell & Non-stem Cell Therapies Industry Trends Table 19. Autologous Stem Cell & Non-stem Cell Therapies Industry Drivers Table 20. Autologous Stem Cell & Non-stem Cell Therapies Industry Opportunities and Challenges Table 21. Autologous Stem Cell & Non-stem Cell Therapies Market Restraints Table 22. Global Top Autologous Stem Cell & Non-stem Cell Therapies Players by Revenue (US$ Million) & (2021-2026) Table 23. Global Autologous Stem Cell & Non-stem Cell Therapies Revenue Market Share by Players (2021-2026) Table 24. Global Autologous Stem Cell & Non-stem Cell Therapies Industry Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Key Players of Autologous Stem Cell & Non-stem Cell Therapies, Headquarters and Area Served Table 26. Global Autologous Stem Cell & Non-stem Cell Therapies Players, Product Type & Application Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Autologous Stem Cell & Non-stem Cell Therapies by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Players Mergers & Acquisitions, Expansion Plans Table 30. North America Autologous Stem Cell & Non-stem Cell Therapies Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 31. North America Autologous Stem Cell & Non-stem Cell Therapies Market Size by Country (2021-2026) & (US$ Million) Table 32. North America Autologous Stem Cell & Non-stem Cell Therapies Market Size by Country (2027-2032) & (US$ Million) Table 33. Europe Autologous Stem Cell & Non-stem Cell Therapies Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Europe Autologous Stem Cell & Non-stem Cell Therapies Market Size by Country (2021-2026) & (US$ Million) Table 35. Europe Autologous Stem Cell & Non-stem Cell Therapies Market Size by Country (2027-2032) & (US$ Million) Table 36. Asia Pacific Autologous Stem Cell & Non-stem Cell Therapies Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Asia Pacific Autologous Stem Cell & Non-stem Cell Therapies Market Size by Region (2021-2026) & (US$ Million) Table 38. Asia Pacific Autologous Stem Cell & Non-stem Cell Therapies Market Size by Country (2027-2032) & (US$ Million) Table 39. South America Autologous Stem Cell & Non-stem Cell Therapies Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. South America Autologous Stem Cell & Non-stem Cell Therapies Market Size by Country (2021-2026) & (US$ Million) Table 41. South America Autologous Stem Cell & Non-stem Cell Therapies Market Size by Country (2027-2032) & (US$ Million) Table 42. Middle East & Africa Autologous Stem Cell & Non-stem Cell Therapies Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Middle East & Africa Autologous Stem Cell & Non-stem Cell Therapies Market Size by Country (2021-2026) & (US$ Million) Table 44. Middle East & Africa Autologous Stem Cell & Non-stem Cell Therapies Market Size by Country (2027-2032) & (US$ Million) Table 45. Anterogen Co., Ltd. Company Information Table 46. Anterogen Co., Ltd. Business Overview Table 47. Anterogen Co., Ltd. Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) & (US$ Million) Table 48. Anterogen Co., Ltd. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 49. Anterogen Co., Ltd. Recent Developments Table 50. APAC Biotech Company Information Table 51. APAC Biotech Business Overview Table 52. APAC Biotech Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) & (US$ Million) Table 53. APAC Biotech Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 54. APAC Biotech Recent Developments Table 55. Bristol-Myers Squibb Company Company Information Table 56. Bristol-Myers Squibb Company Business Overview Table 57. Bristol-Myers Squibb Company Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) & (US$ Million) Table 58. Bristol-Myers Squibb Company Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 59. Bristol-Myers Squibb Company Recent Developments Table 60. CARsgen Therapeutics Holdings Limited Company Information Table 61. CARsgen Therapeutics Holdings Limited Business Overview Table 62. CARsgen Therapeutics Holdings Limited Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) & (US$ Million) Table 63. CARsgen Therapeutics Holdings Limited Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 64. CARsgen Therapeutics Holdings Limited Recent Developments Table 65. Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.) Company Information Table 66. Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.) Business Overview Table 67. Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.) Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) & (US$ Million) Table 68. Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.) Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 69. Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.) Recent Developments Table 70. Gilead Sciences, Inc. Company Information Table 71. Gilead Sciences, Inc. Business Overview Table 72. Gilead Sciences, Inc. Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) & (US$ Million) Table 73. Gilead Sciences, Inc. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 74. Gilead Sciences, Inc. Recent Developments Table 75. Green Cross Holdings Co., Ltd. (GC Cell) Company Information Table 76. Green Cross Holdings Co., Ltd. (GC Cell) Business Overview Table 77. Green Cross Holdings Co., Ltd. (GC Cell) Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) & (US$ Million) Table 78. Green Cross Holdings Co., Ltd. (GC Cell) Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 79. Green Cross Holdings Co., Ltd. (GC Cell) Recent Developments Table 80. Healiva SA Company Information Table 81. Healiva SA Business Overview Table 82. Healiva SA Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) & (US$ Million) Table 83. Healiva SA Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 84. Healiva SA Recent Developments Table 85. ImmunoACT Company Information Table 86. ImmunoACT Business Overview Table 87. ImmunoACT Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) & (US$ Million) Table 88. ImmunoACT Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 89. ImmunoACT Recent Developments Table 90. Iaso Biotherapeutics Company Information Table 91. Iaso Biotherapeutics Business Overview Table 92. Iaso Biotherapeutics Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) & (US$ Million) Table 93. Iaso Biotherapeutics Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 94. Iaso Biotherapeutics Recent Developments Table 95. Johnson & Johnson Company Information Table 96. Johnson & Johnson Business Overview Table 97. Johnson & Johnson Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) & (US$ Million) Table 98. Johnson & Johnson Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 99. Johnson & Johnson Recent Developments Table 100. Lovance Biotherapeutics, Inc. Company Information Table 101. Lovance Biotherapeutics, Inc. Business Overview Table 102. Lovance Biotherapeutics, Inc. Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) & (US$ Million) Table 103. Lovance Biotherapeutics, Inc. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 104. Lovance Biotherapeutics, Inc. Recent Developments Table 105. Novartis AG Company Information Table 106. Novartis AG Business Overview Table 107. Novartis AG Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) & (US$ Million) Table 108. Novartis AG Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 109. Novartis AG Recent Developments Table 110. Pharmicell Co., Ltd. Company Information Table 111. Pharmicell Co., Ltd. Business Overview Table 112. Pharmicell Co., Ltd. Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) & (US$ Million) Table 113. Pharmicell Co., Ltd. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 114. Pharmicell Co., Ltd. Recent Developments Table 115. Regrow Biosciences Pvt Ltd. Company Information Table 116. Regrow Biosciences Pvt Ltd. Business Overview Table 117. Regrow Biosciences Pvt Ltd. Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) & (US$ Million) Table 118. Regrow Biosciences Pvt Ltd. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 119. Regrow Biosciences Pvt Ltd. Recent Developments Table 120. Tegoscience Company Information Table 121. Tegoscience Business Overview Table 122. Tegoscience Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) & (US$ Million) Table 123. Tegoscience Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 124. Tegoscience Recent Developments Table 125. Vericel Corporation Company Information Table 126. Vericel Corporation Business Overview Table 127. Vericel Corporation Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) & (US$ Million) Table 128. Vericel Corporation Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 129. Vericel Corporation Recent Developments Table 130. W (Cayman) Therapeutics Co. Ltd. Company Information Table 131. W (Cayman) Therapeutics Co. Ltd. Business Overview Table 132. W (Cayman) Therapeutics Co. Ltd. Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) & (US$ Million) Table 133. W (Cayman) Therapeutics Co. Ltd. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 134. W (Cayman) Therapeutics Co. Ltd. Recent Developments Table 135. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Autologous Stem Cell & Non-stem Cell Therapies Product Image Figure 5. Global Autologous Stem Cell & Non-stem Cell Therapies Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Global Autologous Stem Cell & Non-stem Cell Therapies Market Share by Type: 2025 VS 2032 Figure 7. CAR-T Product Figure 8. Tumor Infiltrating Lymphocyte Product Figure 9. Global Autologous Stem Cell & Non-stem Cell Therapies Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Autologous Stem Cell & Non-stem Cell Therapies Market Share by Application: 2025 VS 2032 Figure 11. Hospital Product Figure 12. Surgery Center Product Figure 13. Other Product Figure 14. Global Autologous Stem Cell & Non-stem Cell Therapies Market Size (US$ Million), Year-over-Year: 2021-2032 Figure 15. Global Autologous Stem Cell & Non-stem Cell Therapies Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Autologous Stem Cell & Non-stem Cell Therapies Market Share by Region: 2025 VS 2032 Figure 17. Global Autologous Stem Cell & Non-stem Cell Therapies Market Share by Players in 2025 Figure 18. Global Autologous Stem Cell & Non-stem Cell Therapies Manufacturers Established Date Figure 19. Global Top 5 and 10 Autologous Stem Cell & Non-stem Cell Therapies Players Market Share by Revenue in 2025 Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. North America Autologous Stem Cell & Non-stem Cell Therapies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Autologous Stem Cell & Non-stem Cell Therapies Market Share by Country (2021-2032) Figure 23. United States Autologous Stem Cell & Non-stem Cell Therapies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 24. Canada Autologous Stem Cell & Non-stem Cell Therapies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Mexico Autologous Stem Cell & Non-stem Cell Therapies Market Share by Country (2021-2032) Figure 26. Europe Autologous Stem Cell & Non-stem Cell Therapies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Europe Autologous Stem Cell & Non-stem Cell Therapies Market Share by Country (2021-2032) Figure 28. Germany Autologous Stem Cell & Non-stem Cell Therapies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. France Autologous Stem Cell & Non-stem Cell Therapies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 30. U.K. Autologous Stem Cell & Non-stem Cell Therapies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Italy Autologous Stem Cell & Non-stem Cell Therapies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 32. Spain Autologous Stem Cell & Non-stem Cell Therapies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Russia Autologous Stem Cell & Non-stem Cell Therapies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 34. Netherlands Autologous Stem Cell & Non-stem Cell Therapies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Nordic Countries Autologous Stem Cell & Non-stem Cell Therapies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Autologous Stem Cell & Non-stem Cell Therapies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Autologous Stem Cell & Non-stem Cell Therapies Market Share by Country (2021-2032) Figure 38. China Autologous Stem Cell & Non-stem Cell Therapies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 39. Japan Autologous Stem Cell & Non-stem Cell Therapies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 40. South Korea Autologous Stem Cell & Non-stem Cell Therapies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 41. India Autologous Stem Cell & Non-stem Cell Therapies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 42. India Autologous Stem Cell & Non-stem Cell Therapies Market Share by Country (2021-2032) Figure 43. Australia Autologous Stem Cell & Non-stem Cell Therapies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 44. China Taiwan Autologous Stem Cell & Non-stem Cell Therapies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 45. Southeast Asia Autologous Stem Cell & Non-stem Cell Therapies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 46. South America Autologous Stem Cell & Non-stem Cell Therapies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 47. South America Autologous Stem Cell & Non-stem Cell Therapies Market Share by Country (2021-2032) Figure 48. Brazil Autologous Stem Cell & Non-stem Cell Therapies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 49. Argentina Autologous Stem Cell & Non-stem Cell Therapies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 50. Chile Autologous Stem Cell & Non-stem Cell Therapies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 51. Colombia Autologous Stem Cell & Non-stem Cell Therapies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 52. Peru Autologous Stem Cell & Non-stem Cell Therapies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 53. Anterogen Co., Ltd. Revenue Growth Rate in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) Figure 54. APAC Biotech Revenue Growth Rate in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) Figure 55. Bristol-Myers Squibb Company Revenue Growth Rate in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) Figure 56. CARsgen Therapeutics Holdings Limited Revenue Growth Rate in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) Figure 57. Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.) Revenue Growth Rate in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) Figure 58. Gilead Sciences, Inc. Revenue Growth Rate in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) Figure 59. Green Cross Holdings Co., Ltd. (GC Cell) Revenue Growth Rate in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) Figure 60. Healiva SA Revenue Growth Rate in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) Figure 61. ImmunoACT Revenue Growth Rate in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) Figure 62. Iaso Biotherapeutics Revenue Growth Rate in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) Figure 63. Johnson & Johnson Revenue Growth Rate in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) Figure 64. Lovance Biotherapeutics, Inc. Revenue Growth Rate in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) Figure 65. Novartis AG Revenue Growth Rate in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) Figure 66. Pharmicell Co., Ltd. Revenue Growth Rate in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) Figure 67. Regrow Biosciences Pvt Ltd. Revenue Growth Rate in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) Figure 68. Tegoscience Revenue Growth Rate in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) Figure 69. Vericel Corporation Revenue Growth Rate in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026) Figure 70. W (Cayman) Therapeutics Co. Ltd. Revenue Growth Rate in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026)

Scope & coverage.

Types
  • CAR-T
  • Tumor Infiltrating Lymphocyte
Applications
  • Hospital
  • Surgery Center
  • Other
Companies covered
  • Anterogen Co., Ltd.
  • APAC Biotech
  • Bristol-Myers Squibb Company
  • CARsgen Therapeutics Holdings Limited
  • Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
  • Gilead Sciences, Inc.
  • Green Cross Holdings Co., Ltd. (GC Cell)
  • Healiva SA
  • ImmunoACT
  • Iaso Biotherapeutics
  • Johnson & Johnson
  • Lovance Biotherapeutics, Inc.
  • Novartis AG
  • Pharmicell Co., Ltd.
  • Regrow Biosciences Pvt Ltd.
  • Tegoscience
  • Vericel Corporation
  • W (Cayman) Therapeutics Co. Ltd.

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Autologous Stem Cell & Non-stem Cell Therapies by Type
  3. 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
  4. 2.2.2 CAR-T
  5. 2.2.3 Tumor Infiltrating Lymphocyte
  6. 2.3 Autologous Stem Cell & Non-stem Cell Therapies by Application
  7. 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  8. 2.3.2 Hospital
  9. 2.3.3 Surgery Center
  10. 2.3.4 Other
  11. 2.4 Assumptions and Limitations
3 Autologous Stem Cell & Non-stem Cell Therapies Breakdown Data by Type
  1. 3.1 Global Autologous Stem Cell & Non-stem Cell Therapies Historic Market Size by Type (2021-2026)
  2. 3.2 Global Autologous Stem Cell & Non-stem Cell Therapies Forecasted Market Size by Type (2027-2032)
4 Autologous Stem Cell & Non-stem Cell Therapies Breakdown Data by Application
  1. 4.1 Global Autologous Stem Cell & Non-stem Cell Therapies Historic Market Size by Application (2021-2026)
  2. 4.2 Global Autologous Stem Cell & Non-stem Cell Therapies Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
  1. 5.1 Global Autologous Stem Cell & Non-stem Cell Therapies Market Perspective (2021-2032)
  2. 5.2 Global Autologous Stem Cell & Non-stem Cell Therapies Growth Trends by Region
  3. 5.2.1 Global Autologous Stem Cell & Non-stem Cell Therapies Market Size by Region: 2021 VS 2025 VS 2032
  4. 5.2.2 Autologous Stem Cell & Non-stem Cell Therapies Historic Market Size by Region (2021-2026)
  5. 5.2.3 Autologous Stem Cell & Non-stem Cell Therapies Forecasted Market Size by Region (2027-2032)
  6. 5.3 Autologous Stem Cell & Non-stem Cell Therapies Market Dynamics
  7. 5.3.1 Autologous Stem Cell & Non-stem Cell Therapies Industry Trends
  8. 5.3.2 Autologous Stem Cell & Non-stem Cell Therapies Market Drivers
  9. 5.3.3 Autologous Stem Cell & Non-stem Cell Therapies Market Challenges
  10. 5.3.4 Autologous Stem Cell & Non-stem Cell Therapies Market Restraints
6 Market Competitive Landscape by Players
  1. 6.1 Global Top Autologous Stem Cell & Non-stem Cell Therapies Players by Revenue
  2. 6.1.1 Global Top Autologous Stem Cell & Non-stem Cell Therapies Players by Revenue (2021-2026)
  3. 6.1.2 Global Autologous Stem Cell & Non-stem Cell Therapies Revenue Market Share by Players (2021-2026)
  4. 6.2 Global Autologous Stem Cell & Non-stem Cell Therapies Industry Players Ranking, 2023 VS 2024 VS 2025
  5. 6.3 Global Key Players of Autologous Stem Cell & Non-stem Cell Therapies Head Office and Area Served
  6. 6.4 Global Autologous Stem Cell & Non-stem Cell Therapies Players, Product Type & Application
  7. 6.5 Global Autologous Stem Cell & Non-stem Cell Therapies Manufacturers Established Date
  8. 6.6 Global Autologous Stem Cell & Non-stem Cell Therapies Market CR5 and HHI
  9. 6.7 Global Players Mergers & Acquisition
7 North America
  1. 7.1 North America Autologous Stem Cell & Non-stem Cell Therapies Market Size (2021-2032)
  2. 7.2 North America Autologous Stem Cell & Non-stem Cell Therapies Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 7.3 North America Autologous Stem Cell & Non-stem Cell Therapies Market Size by Country (2021-2026)
  4. 7.4 North America Autologous Stem Cell & Non-stem Cell Therapies Market Size by Country (2027-2032)
  5. 7.5 United States
  6. 7.5 United States
  7. 7.6 Canada
  8. 7.7 Mexico
8 Europe
  1. 8.1 Europe Autologous Stem Cell & Non-stem Cell Therapies Market Size (2021-2032)
  2. 8.2 Europe Autologous Stem Cell & Non-stem Cell Therapies Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 8.3 Europe Autologous Stem Cell & Non-stem Cell Therapies Market Size by Country (2021-2026)
  4. 8.4 Europe Autologous Stem Cell & Non-stem Cell Therapies Market Size by Country (2027-2032)
  5. 8.5 Germany
  6. 8.6 France
  7. 8.7 U.K.
  8. 8.8 Italy
  9. 8.9 Spain
  10. 8.10 Russia
  11. 8.11 Netherlands
  12. 8.12 Nordic Countries
9 Asia-Pacific
  1. 9.1 Asia-Pacific Autologous Stem Cell & Non-stem Cell Therapies Market Size (2021-2032)
  2. 9.2 Asia-Pacific Autologous Stem Cell & Non-stem Cell Therapies Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 9.3 Asia-Pacific Autologous Stem Cell & Non-stem Cell Therapies Market Size by Country (2021-2026)
  4. 9.4 Asia-Pacific Autologous Stem Cell & Non-stem Cell Therapies Market Size by Country (2027-2032)
  5. 9.5 China
  6. 9.6 Japan
  7. 9.7 South Korea
  8. 9.8 India
  9. 9.9 Australia
  10. 9.10 China Taiwan
  11. 9.11 Southeast Asia
10 South America
  1. 10.1 South America Autologous Stem Cell & Non-stem Cell Therapies Market Size (2021-2032)
  2. 10.2 South America Autologous Stem Cell & Non-stem Cell Therapies Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 10.3 South America Autologous Stem Cell & Non-stem Cell Therapies Market Size by Country (2021-2026)
  4. 10.4 South America Autologous Stem Cell & Non-stem Cell Therapies Market Size by Country (2027-2032)
  5. 10.5 Brazil
  6. 10.6 Argentina
  7. 10.7 Chile
  8. 10.8 Colombia
  9. 10.9 Peru
11 Middle East & Africa
  1. 11.1 Middle East & Africa Autologous Stem Cell & Non-stem Cell Therapies Market Size (2021-2032)
  2. 11.2 Middle East & Africa Autologous Stem Cell & Non-stem Cell Therapies Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 11.3 Middle East & Africa Autologous Stem Cell & Non-stem Cell Therapies Market Size by Country (2021-2026)
  4. 11.4 Middle East & Africa Autologous Stem Cell & Non-stem Cell Therapies Market Size by Country (2027-2032)
  5. 11.5 Saudi Arabia
  6. 11.6 Israel
  7. 11.7 United Arab Emirates
  8. 11.8 Turkey
  9. 11.9 Iran
  10. 11.10 Egypt
12 Players Profiled
  1. 12.1 Anterogen Co., Ltd.
  2. 12.1.1 Anterogen Co., Ltd. Company Information
  3. 12.1.2 Anterogen Co., Ltd. Business Overview
  4. 12.1.3 Anterogen Co., Ltd. Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026)
  5. 12.1.4 Anterogen Co., Ltd. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  6. 12.1.5 Anterogen Co., Ltd. Recent Developments
  7. 12.2 APAC Biotech
  8. 12.2.1 APAC Biotech Company Information
  9. 12.2.2 APAC Biotech Business Overview
  10. 12.2.3 APAC Biotech Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026)
  11. 12.2.4 APAC Biotech Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  12. 12.2.5 APAC Biotech Recent Developments
  13. 12.3 Bristol-Myers Squibb Company
  14. 12.3.1 Bristol-Myers Squibb Company Company Information
  15. 12.3.2 Bristol-Myers Squibb Company Business Overview
  16. 12.3.3 Bristol-Myers Squibb Company Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026)
  17. 12.3.4 Bristol-Myers Squibb Company Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  18. 12.3.5 Bristol-Myers Squibb Company Recent Developments
  19. 12.4 CARsgen Therapeutics Holdings Limited
  20. 12.4.1 CARsgen Therapeutics Holdings Limited Company Information
  21. 12.4.2 CARsgen Therapeutics Holdings Limited Business Overview
  22. 12.4.3 CARsgen Therapeutics Holdings Limited Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026)
  23. 12.4.4 CARsgen Therapeutics Holdings Limited Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  24. 12.4.5 CARsgen Therapeutics Holdings Limited Recent Developments
  25. 12.5 Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
  26. 12.5.1 Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.) Company Information
  27. 12.5.2 Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.) Business Overview
  28. 12.5.3 Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.) Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026)
  29. 12.5.4 Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.) Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  30. 12.5.5 Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.) Recent Developments
  31. 12.6 Gilead Sciences, Inc.
  32. 12.6.1 Gilead Sciences, Inc. Company Information
  33. 12.6.2 Gilead Sciences, Inc. Business Overview
  34. 12.6.3 Gilead Sciences, Inc. Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026)
  35. 12.6.4 Gilead Sciences, Inc. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  36. 12.6.5 Gilead Sciences, Inc. Recent Developments
  37. 12.7 Green Cross Holdings Co., Ltd. (GC Cell)
  38. 12.7.1 Green Cross Holdings Co., Ltd. (GC Cell) Company Information
  39. 12.7.2 Green Cross Holdings Co., Ltd. (GC Cell) Business Overview
  40. 12.7.3 Green Cross Holdings Co., Ltd. (GC Cell) Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026)
  41. 12.7.4 Green Cross Holdings Co., Ltd. (GC Cell) Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  42. 12.7.5 Green Cross Holdings Co., Ltd. (GC Cell) Recent Developments
  43. 12.8 Healiva SA
  44. 12.8.1 Healiva SA Company Information
  45. 12.8.2 Healiva SA Business Overview
  46. 12.8.3 Healiva SA Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026)
  47. 12.8.4 Healiva SA Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  48. 12.8.5 Healiva SA Recent Developments
  49. 12.9 ImmunoACT
  50. 12.9.1 ImmunoACT Company Information
  51. 12.9.2 ImmunoACT Business Overview
  52. 12.9.3 ImmunoACT Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026)
  53. 12.9.4 ImmunoACT Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  54. 12.9.5 ImmunoACT Recent Developments
  55. 12.10 Iaso Biotherapeutics
  56. 12.10.1 Iaso Biotherapeutics Company Information
  57. 12.10.2 Iaso Biotherapeutics Business Overview
  58. 12.10.3 Iaso Biotherapeutics Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026)
  59. 12.10.4 Iaso Biotherapeutics Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  60. 12.10.5 Iaso Biotherapeutics Recent Developments
  61. 12.11 Johnson & Johnson
  62. 12.11.1 Johnson & Johnson Company Information
  63. 12.11.2 Johnson & Johnson Business Overview
  64. 12.11.3 Johnson & Johnson Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026)
  65. 12.11.4 Johnson & Johnson Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  66. 12.11.5 Johnson & Johnson Recent Developments
  67. 12.12 Lovance Biotherapeutics, Inc.
  68. 12.12.1 Lovance Biotherapeutics, Inc. Company Information
  69. 12.12.2 Lovance Biotherapeutics, Inc. Business Overview
  70. 12.12.3 Lovance Biotherapeutics, Inc. Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026)
  71. 12.12.4 Lovance Biotherapeutics, Inc. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  72. 12.12.5 Lovance Biotherapeutics, Inc. Recent Developments
  73. 12.13 Novartis AG
  74. 12.13.1 Novartis AG Company Information
  75. 12.13.2 Novartis AG Business Overview
  76. 12.13.3 Novartis AG Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026)
  77. 12.13.4 Novartis AG Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  78. 12.13.5 Novartis AG Recent Developments
  79. 12.14 Pharmicell Co., Ltd.
  80. 12.14.1 Pharmicell Co., Ltd. Company Information
  81. 12.14.2 Pharmicell Co., Ltd. Business Overview
  82. 12.14.3 Pharmicell Co., Ltd. Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026)
  83. 12.14.4 Pharmicell Co., Ltd. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  84. 12.14.5 Pharmicell Co., Ltd. Recent Developments
  85. 12.15 Regrow Biosciences Pvt Ltd.
  86. 12.15.1 Regrow Biosciences Pvt Ltd. Company Information
  87. 12.15.2 Regrow Biosciences Pvt Ltd. Business Overview
  88. 12.15.3 Regrow Biosciences Pvt Ltd. Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026)
  89. 12.15.4 Regrow Biosciences Pvt Ltd. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  90. 12.15.5 Regrow Biosciences Pvt Ltd. Recent Developments
  91. 12.16 Tegoscience
  92. 12.16.1 Tegoscience Company Information
  93. 12.16.2 Tegoscience Business Overview
  94. 12.16.3 Tegoscience Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026)
  95. 12.16.4 Tegoscience Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  96. 12.16.5 Tegoscience Recent Developments
  97. 12.17 Vericel Corporation
  98. 12.17.1 Vericel Corporation Company Information
  99. 12.17.2 Vericel Corporation Business Overview
  100. 12.17.3 Vericel Corporation Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026)
  101. 12.17.4 Vericel Corporation Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  102. 12.17.5 Vericel Corporation Recent Developments
  103. 12.18 W (Cayman) Therapeutics Co. Ltd.
  104. 12.18.1 W (Cayman) Therapeutics Co. Ltd. Company Information
  105. 12.18.2 W (Cayman) Therapeutics Co. Ltd. Business Overview
  106. 12.18.3 W (Cayman) Therapeutics Co. Ltd. Revenue in Autologous Stem Cell & Non-stem Cell Therapies Business (2021-2026)
  107. 12.18.4 W (Cayman) Therapeutics Co. Ltd. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  108. 12.18.5 W (Cayman) Therapeutics Co. Ltd. Recent Developments
13 Report Conclusion
    14 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst